Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
900.1 USD | +1.06% | -0.92% | +2.27% |
04-26 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
04-26 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.27% | 96.09B | |
-2.66% | 102B | |
+2.13% | 22.28B | |
-16.84% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.96% | 16.09B | |
+6.57% | 13.83B | |
+32.49% | 11.97B | |
+310.32% | 8.78B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $765 From $775, Keeps Overweight Rating